T1	Participants 719 787	Patients and tumors were monitored for adverse events and responses.
T2	Participants 788 902	RESULTS rAd-p53-specific p53 mRNA was detected in postinjection of rAd-p53 biopsies from 16 (94.1%) of 17 patients
